

The Vibrant Science and Technology Company

353
years

The Merck family holds 70% of the publicly listed company and has retained ownership since 1668.

58,000
employees globally

As of 2020, people from 136 nations work for the company in 66 countries.

17.5
billion € sales

Between 2005 and 2020, we nearly tripled our global sales from 5.9 billion € to 17.5 billion €.

2.3
billion € R&D investments

In 2020, we spent globally **2.3 billion €** on Research & Development.

Our Businesses in Europe



5 billion € sales in Europe in 2020.



Almost **2 billion €** R&D investments in Europe in 2020.



More than **26,500** employees in Europe in 2020.

That is almost **85 %** of Merck's worldwide R&D investments.



- Healthcare
- Life Science
- Performance Materials

HEALTHCARE



We offer **prescription drugs** and solutions to treat cancer, multiple sclerosis, infertility, growth disorders as well as certain cardiovascular and metabolic diseases. The work of our Healthcare business can help to make a difference to millions of lives. We put our patients at the center of everything we do.

LIFE SCIENCE



By providing scientists and engineers with best-in-class **lab materials, technologies and services**, we make research and biotech production simpler, faster and safer. Our **300,000 products** include lab water systems, gene editing tools, antibodies, cell lines, and end-to-end systems to manufacture drugs.

electronics



Our Electronics business sector is the company behind the companies, advancing digital living. It comprises four business units: Semiconductor Materials, Delivery Systems & Services, Display Solutions, and Surface Solutions. All together, we develop specialty chemicals for demanding applications, from **liquid crystals and OLED materials** for displays and lighting to **effect pigments** for coatings and cosmetics through to **high-tech materials** for the electronics industry.



More information:
www.merckgroup.com



Economic Footprint



Merck employing more than 26,500 people in Europe lead to the **employment of more than 96,000 people** within the European labor market.



Merck achieved a remarkable **17% R&D-intensity**, surpassing the EU's target rate for companies of 3% for the year 2020.



We placed **5.3 billion €** worth of orders with its **European suppliers**, thus, supporting the economy.



Merck achieved a value creation of more than **300,000 €** per employee, which shows how productive the company is.



Merck Europe **supports the local economy and creates resilience** in its supply chain by generating 73% of value inhouse.

The economic footprint information (2019) has been calculated by WifOR, a global independent economic research institute.

Science & Technology

Merck and European Space Agency will continue to cooperate intensively in the fields of innovation, **digitalization** and materials research. With respect to innovation, the focus will be on the fields of Biosensing and Biointerfaces, Clean Meat and Liquid Biopsy technologies.

Life Science offers a broad portfolio of products for the use of **CRISPR** technology, which enables genome modification. This helps to find new therapies.

Breakthroughs begin with **curiosity**: Over **3,400** people work in the R&D team in Europe. Merck holds more than **13,400** patents or patent applications in Europe.

The **Innovation center** in Darmstadt, Germany, is designed to bring together people, technologies and skills under one roof in the heart of Europe.

In Healthcare, we aspire with our research pipeline to make a positive difference for patients – always with the purpose to help create, improve, and prolong **life**. Our main research areas include oncology, immuno-oncology, and immunology including multiple sclerosis.

At our **R&D Hubs** in Darmstadt, Boston, Beijing, and Tokyo our researchers work on new treatments as well as products for patients and customers.

As a leading supplier, our team in Electronics in Darmstadt, Germany, develops highly pure, reliable, and efficient **OLED** materials for innovative products for the global market.

Environmental & Social Engagement

We use an assessment tool from the European Chemical Industry Council to evaluate **water management** at our facilities. By beginning of 2019, we had curbed our water use in water-stressed areas by ca. 10.8%.



Our solvent Cyrene™ is derived from waste cellulose and is used as a more **sustainable alternative** to substances, which are classified as toxic to reproduction. We were awarded € 12 million towards building a new Cyrene™ production facility in Europe by the EU research and innovation program Horizon 2020.



We support developments related to the European Green Deal and are preparing to translate the pertinent elements into a dedicated chemicals sustainability strategy for our company.



The **Merck Foundation**, the company's philanthropic arm, supports programs that raise awareness of disease prevention and early detection and expand professional capabilities in healthcare and scientific research. **The Merck Family Foundation** fulfills the Merck family's wish to promote civil society at the locations where Merck operates.



The **Deutsche Philharmonie Merck** goes on international concert tours and has played almost everywhere in Europe. We offer workshops where children and adolescents can play in the orchestra.



Literature Award for bridge builder: We yearly award worldwide five prizes, two in Europe, e.g. for scientific literature made available for a broad audience.